Journal francais d'ophtalmologie · 2026
One-year results of XEN 45® gel stent in open-angle glaucoma and its impact on glaucoma medication-related costs.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guedes R A P, Moraes D A G, Gravina D M, Guedes V M P, Chaoubah A
Аннотация
PURPOSE: To assess the 1-year efficacy and safety of the XEN 45® gel stent (XEN) and its impact on glaucoma medication-related costs.
METHODS: This retrospective study included patients with open-angle glaucoma who underwent XEN implantation. We evaluated the ability of the procedure to reduce intraocular pressure, the amount of glaucoma medications required, complications and re-interventions over a 12-month follow-up period. The main outcome measures were: (1) probability of success (intraocular pressure<18mmHg with no medications, complications, or re-interventions) at 1 year; and (2) monthly cost of glaucoma medications during follow-up. We also evaluated the visual field at baseline and month 12.
RESULTS: The study population consisted of 130 patients (mean [± standard deviation] age: 66.5±12.2 years). We observed 36.2% and 90.0% reductions in the mean intraocular pressure and number of medications, respectively (P<0.001 for both analysis). Mean (± standard deviation) monthly medication costs per patient decreased from 69.16±13.67 dollars at baseline to 5.18±14.70 dollars at month 12, a 92.5% reduction. The probability of success was 63.8%. No visual field worsening or vision-threatening complications were observed.
CONCLUSION: The XEN procedure resulted in a significant reduction in intraocular pressure, number of medications, and glaucoma medication-related costs while achieving stability of the visual field over a 1-year period.
METHODS: This retrospective study included patients with open-angle glaucoma who underwent XEN implantation. We evaluated the ability of the procedure to reduce intraocular pressure, the amount of glaucoma medications required, complications and re-interventions over a 12-month follow-up period. The main outcome measures were: (1) probability of success (intraocular pressure<18mmHg with no medications, complications, or re-interventions) at 1 year; and (2) monthly cost of glaucoma medications during follow-up. We also evaluated the visual field at baseline and month 12.
RESULTS: The study population consisted of 130 patients (mean [± standard deviation] age: 66.5±12.2 years). We observed 36.2% and 90.0% reductions in the mean intraocular pressure and number of medications, respectively (P<0.001 for both analysis). Mean (± standard deviation) monthly medication costs per patient decreased from 69.16±13.67 dollars at baseline to 5.18±14.70 dollars at month 12, a 92.5% reduction. The probability of success was 63.8%. No visual field worsening or vision-threatening complications were observed.
CONCLUSION: The XEN procedure resulted in a significant reduction in intraocular pressure, number of medications, and glaucoma medication-related costs while achieving stability of the visual field over a 1-year period.